

## PART I – RAPID ANTIGEN TEST

<b>Q1: Is your country currently using/considering to use rapid antigen-tests?</b>	
<i>Options</i>	<i>Please provide your answer here</i>
<b>Yes</b> , using in context of pilots and studies (e.g. to assess performance or potential use)	Yes, studies have started to assess the performance of a selection of tests
<b>Yes</b> , using for diagnostic purposes or public health measures (e.g. quarantine)	
<b>Yes</b> , considering to use	
<b>No</b> , not of interest	
<b>Other</b>	

<b>Q2: If yes, which specific antigen tests are you using/considering?</b>
<i>Please provide details (e.g. brand, company, details on sensitivity and specificity) Please indicate in case the antigen tests you are using/studying are mentioned in this database used by WHO: <a href="https://www.finddx.org/covid-19/pipeline/">https://www.finddx.org/covid-19/pipeline/</a></i>
<p>Several commercially available antigen tests and several tests that are being developed in the Netherlands</p> <p>First tests in selection process:</p> <p>BD VeriTor COVID antigen test (Becton Dickinson)</p> <ul style="list-style-type: none"> <li>- sensitivity (84%) and specificity (100%)</li> </ul> <p>SARS-CoV-2 Rapid Antigen Test (roche)</p> <ul style="list-style-type: none"> <li>- sensitivity (96.5%) and specificity (99.7%)</li> <li>- in evaluation by FINDx</li> </ul> <p>STANDARD F COVID-19 Ag FIA (Biosensor)</p> <ul style="list-style-type: none"> <li>- sensitivity (100%) and specificity (100%)</li> </ul> <p>Sofia SARS Antigen FIA (quidel)</p> <ul style="list-style-type: none"> <li>- sensitivity (96.7%) and specificity (100%)</li> </ul> <p>Abott panbio (abbott)</p> <ul style="list-style-type: none"> <li>- sensitivity (93.3%) and specificity (99.4%)</li> <li>- in evaluation by FINDx</li> </ul>

<b>Q3: If yes, which criteria were used in your country to select a certain antigen test for use/piloting?</b>
Combination of WHO criteria, availability and several other practical considerations.

--

<b>Q4: If yes, in which context or situation are you using/considering to use antigen tests?</b>	
<i>Options</i>	<i>Please provide your answer here</i>
Points of entry (airports, ports)	Depends on diagnostic performance of the assay
Local outbreak clusters	Depends on diagnostic performance of the assay
Specific target groups or settings (e.g. healthcare workers, schools, prisons)	Depends on diagnostic performance of the assay
To replace RT-PCR due to restricted capacities/unavailability of this test	Depends on diagnostic performance of the assay
To monitor trends in disease incidence in communities	Depends on diagnostic performance of the assay
Other	Not Applicable. Studies have started to evaluate the performance of tests.

<b>Q5: If yes, does the result need to be confirmed by RT-PCR?</b>	
<i>Options</i>	<i>Please provide your answer here</i>
Yes, positive result needs to be confirmed by RT-PCR	Depends on diagnostic performance of the assay
Yes, negative result needs to be confirmed by RT-PCR	Depends on diagnostic performance of the assay
No, this is not necessary	
Other	Since tests are only used in studies, RT-PCR is used for cross validation

<b>Q6: If yes, do you accept the result as a basis for public health measures (e.g. quarantine)</b>	
<i>Options</i>	<i>Please provide your answer here</i>
Yes, the antigen test result alone is accepted for public health measures	Depends on diagnostic performance of the assay
Yes, the antigen test result, confirmed by RT-PCR, is accepted for public health measures	Depends on diagnostic performance of the assay
No, the antigen test result is not accepted as a basis for public health measures	Depends on diagnostic performance of the assay
Other	

## PART II – MUTUAL RECOGNITION OF COVID-19 TESTS

<b>Q1: Do you currently experience any problems regarding the mutual recognition of COVID-19 test results?</b>	
<i>Options</i>	<i>Please provide your answer here</i>
<b>Yes</b> , in the context of incoming travellers to our country	
<b>Yes</b> , in the context of people from our country travelling to another MS	
<b>Yes</b> , in a context different than cross-border issues	
<b>No</b> , we do not have any problems as we don't require incoming travellers to have a negative test result with them	
<b>No</b> , we do not have any problems in the context of people from our country travelling to other MS	
<b>Other</b>	Not Applicable

<b>Q2: What type of tests should be recognised between MS? Only RT-PCR test results, also antigen test results, any other?</b>
NA

<b>Q3: How could the legitimacy of the test result be ensured? E.g. do we need a list of labs and entities per MS that are authorised for COVID-19 testing?</b>
NA

<b>Q4: Should only the results of CE marked tests be accepted?</b>
NA

<b>Q5: What kind of information should be provided by the test result? For example: Name of the person, Details of the lab, Type of test, Result of the test, Date and time when the test was taken</b>
NA

**Q6: In which language should the test result be made available?**

NA

**Q7: Do you believe the development of an EU platform to facilitate the mutual recognition of test results between MS would be helpful?**

NA